A Phase 1B, Repeated Dose Study, to Evaluate the Safety, PD and PK Profile of CM-101 in NAFLD Patients With Normal Liver Function Tests and Stable NAFLD/NASH Patients With NAFLD Activity Score (NAS) < 3-The SPARK Study
Latest Information Update: 19 Jun 2024
At a glance
- Drugs CM 101 (Primary) ; CM 101 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacodynamics
- Acronyms SPARK
- Sponsors Chemomab Therapeutics
- 18 Jun 2024 According to a ChemomAb media release, the company published the data of this trial in the online edition of the journal Drug Safety
- 13 Sep 2023 Status changed from recruiting to completed.
- 05 Jan 2021 According to a ChemomAb media release, Prof. Rifat Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel, is a Principal Investigator of this phase 1b study.